{"groups":[{"description":"Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy\n\nLenalidomide Induction: Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.\n\nSequential Maintenance Therapy: Subjects who achieve \\>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \\> stable disease (SD) from maintenance (per discussion with physician):\n\n* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis\n* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle\n* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7\n* Prednisone 60 mg /m2 po daily on","id":"FG000","title":"High-risk Multiple Myeloma"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Active Hepatitis"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Induction Therapy"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"NOT COMPLETED"}],"title":"Two Years of Maintenance Therapy"}],"recruitmentDetails":"Recruitment began in July, 2008 and ended in October, 2010. Subjects were identified from Duke University Medical Center Hematologic Malignancies and Cellular Therapy program and University of North Carolina at Chapel Hill Lineberger Cancer Center for all demographic groups who meet the eligibility criteria."}